智飞生物重组带状疱疹ZFA01佐剂疫苗（CHO细胞）临床试验获批准

Core Viewpoint - Zhifei Biological has received approval from the National Medical Products Administration for clinical trials of its recombinant varicella-zoster virus vaccine (ZFA01) in individuals aged 40 and above, marking a significant advancement in its innovative adjuvant technology platform [1] Group 1: Company Developments - The clinical trial approval for the ZFA01 vaccine is a result of the company's focus on innovation and strengthening core technological capabilities [1] - Successful progress of this project is expected to enrich the company's adult vaccine portfolio and enhance its product layout [1] - The development of this vaccine will further solidify the company's market position in the vaccine industry [1]